First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
The bull case is simple: analysts see revenue climbing from $16M to $15M as successful completion of phase 1 clinical trials for lead product candidate, with 85% efficacy reported.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.